Lead Investigator: Junjie Zhuo, Hainan University
Title of Proposal Research: Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles with Clinical Profiles in the Progression of Alzheimer’s Disease
Vivli Data Request: 7462
Funding Source: the Natural Science Foundation of China (Grant Nos. 81701781)
Potential Conflicts of Interest: None
Summary of the Proposed Research:
• The project background：
With the arrival of the global aging society, there is a new case of dementia every 3 seconds in the world. Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60-70%. Currently, we are facing the huge social and economic pressure brought by AD. Unfortunately, there are no drugs known to effectively treat Alzheimer’s disease.
• Necessity of the research;
Recent two years, two new drugs probed by United States Food and Drug Administration and China National Medical Products Administration, as well as some ongoing clinical trials suggest that these drugs maybe delay the progression of AD when used in the early stage of AD. However, the early stage of AD not easy to identified. In addition, some previous studies showed that different subgroups in the early stage of AD maybe exist different cognition decline pattern.
• How the research will add to medical science or patient care;
This research will help to optimize the design of clinical trials in the future.
Requested Studies:
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer’s Disease (AMARANTH)
Data Contributor: AstraZeneca
Study ID: NCT02245737
Sponsor ID: D5010C00009
A Study of Lanabecestat (LY3314814) in Early Alzheimer’s Disease Dementia
Data Contributor: AstraZeneca
Study ID: NCT02972658
Sponsor ID: D5010C00030
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer’s Disease Dementia (DAYBREAK-ALZ)
Data Contributor: AstraZeneca
Study ID: NCT02783573
Sponsor ID: D5010C00011